REPLIMUNE GROUP, INC. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
REPLIMUNE GROUP, INC. (REPL) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of $1.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-14
- REPLIMUNE GROUP, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-06-30 was $1.27M.
- REPLIMUNE GROUP, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-06-30 was -$1.62M.
- REPLIMUNE GROUP, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-06-30 was -$35.00K, a 369.23% decline year-over-year.
- REPLIMUNE GROUP, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-06-30 was $13.00K, a 99.32% decline year-over-year.
- REPLIMUNE GROUP, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2026 was $1.11M, a 253.02% increase from fiscal 2025.
- REPLIMUNE GROUP, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $315.00K.
- REPLIMUNE GROUP, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$86.00K.
- REPLIMUNE GROUP, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was -$109.00K, a 113.33% decline from fiscal 2022.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.27M 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | $1.11M 10-K · filed 2026-06-29 | |||
| 2025-12-31 | $1.06M 10-Q · filed 2026-02-03 | |||
| 2025-09-30 | $26.00K 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | -$1.62M 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | $315.00K 10-K · filed 2026-06-29 | |||
| 2024-12-31 | -$125.00K 10-Q · filed 2026-02-03 | |||
| 2024-09-30 | $26.00K 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | -$35.00K 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | -$86.00K 10-K · filed 2025-05-22 | |||
| 2023-12-31 | -$30.00K 10-Q · filed 2025-02-12 | |||
| 2023-09-30 | -$3.00K 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | $13.00K 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | -$109.00K 10-K · filed 2024-05-16 | |||
| 2022-12-31 | $4.34M 10-Q · filed 2024-02-08 | |||
| 2022-09-30 | $4.35M 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | $1.92M 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | $818.00K 10-K · filed 2023-05-18 | |||
| 2021-12-31 | $621.00K 10-Q · filed 2023-02-09 | |||
| 2021-09-30 | $516.00K 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $212.00K 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $721.00K 10-K · filed 2022-05-19 | |||
| 2020-12-31 | $1.06M 10-Q · filed 2022-02-03 | |||
| 2020-09-30 | $540.00K 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | -$1.00K 10-Q · filed 2021-08-06 | |||
| 2020-03-31 | -$135.00K 10-K · filed 2021-05-20 | |||
| 2019-12-31 | -$20.00K 10-Q · filed 2021-02-04 | |||
| 2019-09-30 | -$304.00K 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | -$137.00K 10-Q · filed 2020-08-07 | |||
| 2019-03-31 | -$839.00K 10-K · filed 2020-06-03 | |||
| 2018-12-31 | -$1.01M 10-Q · filed 2020-02-13 | |||
| 2018-09-30 | -$928.00K 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | -$731.00K 10-Q · filed 2019-08-14 | |||
| 2018-03-31 | $2.30M 10-K · filed 2020-06-03 | |||
| 2017-12-31 | $1.61M 10-Q · filed 2019-02-14 | |||
| 2017-03-31 | -$1.42M 10-K · filed 2019-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |